Zeta Corporation of Arcadia, CA at MEDICA 2022 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Company news

Date

Topic

18 Aug 2022

Rabbit monoclonals

RAbMono™ (Rabbit Monoclonals)
RAbMono™, Rabbit monoclonals designed and developed at Zeta are uniquely produced and target-validated for IHC on FFPE tissue sections. Zeta’s RAbMono™ (Rabbit Monoclonal) antibodies stand out because of their superior specificity, low background, and high affinity.

In contrast to typical mouse monoclonal technology, Zeta has achieved a unique and effective rabbit monoclonal production platform based on our unmatched expertise in the field.  Generally, Rabbit Monoclonals are characterized by 10 to 100 times higher affinity than Mouse Monoclonals.  The rabbit’s immune system is better equipped to generate a response to smaller antigens that are not detected in mice.

As a result, Rabbit Monoclonals are becoming increasingly popular in the immunohistochemical detection of tumor markers in humans.

More Less